Specifically, the reauthorization bill includes provisions that would:
• Enhance the ability of the FDA and increases oversight of the pharmaceutical industry to ensure U.S. prescription and over-the-counter drugs are both safe and effective
• Expedite FDA approval and provide more flexibility for breakthrough drugs or treatments that show dramatic responses early in development, while still ensuring drug safety and efficacy
• Reduce regulatory burdens that unnecessarily delay new medical devices from reaching the market, such as delays in the 510(k) process, and give the FDA tools to improve oversight and tracking of medical devices after they are approved
• Spur development of new drugs to treat increasing cases of bacterial infections resistant to conventional antibiotics
The bill now faces a full Senate vote.
Related Articles on Patient Safety:
6 HFAP-Accredited Hospitals Recognized
Translators in the ER May Decrease Medical Errors
APIC, SHEA Partner With HHS For Partnership in Prevention Award
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
